SEAPORT THERAPEUTICS INC (SPTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$24.86+2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SPTX — earnings miss
Dated 2026-08-03
Results of Operations and Financial Condition. On August 3, 2026, Seaport Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Section 1…
Why it matters: Finishing these studies is key to moving Glyph2BLSD into clinical trials. This could lead to new treatment options.
Supportive ifFirst studies for Glyph2BLSD will be done by the end of 2027.
Worry ifStudies are not completed by the end of 2027.
Why it matters: Data from this trial will show how GlyphAllo affects driving performance. Positive results could support its use in treating anxiety and depression.
Supportive ifThe Phase 1 driving simulation trial for GlyphAllo will report data in 2H 2026.
Worry ifNo data is reported. Results show a negative impact on driving performance.
Why it matters: This data shows how GlyphAllo affects driving. Good results may help further development.
Supportive ifThe Phase 1 driving simulation trial shows good early results.
Worry ifTopline data from the trial shows negative effects on driving performance.
Why it matters: Starting this trial shows progress in making treatments for anxiety disorder.
Supportive ifAnnouncement of the start of the Phase 2a trial for GlyphAgo.
Worry ifNo announcement or delays in starting the Phase 2a trial for GlyphAgo.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$299 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $640 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,314 loss on $10,000 · 23.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This data is key to understanding how well GlyphAllo treats depression.
Supportive ifTopline data from the Phase 2b BUOY-1 trial is reported as positive.
Worry ifTopline data from the trial shows GlyphAllo does not work for depression.